Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma - Trial NCT01480050
Access comprehensive clinical trial information for NCT01480050 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and is currently Completed. The study focuses on Brain and Central Nervous System Tumors. Target enrollment is 28 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Timeline & Enrollment
Phase 1
May 31, 2012
Jun 01, 2017
Primary Outcome
Maximum-tolerated dose of mibefradil dihydrochloride,Dose-limiting toxicity
Summary
RATIONALE: Mibefradil dihydrochloride may stop the growth of tumor cells by blocking some of
 the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in
 different ways to stop the growth of tumor cells, either by killing the cells or by stopping
 them from dividing.
 
 PURPOSE: This phase I trial is studying the best dose of mibefradil dihydrochloride when
 given together with temozolomide in treating patients with glioma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01480050
Non-Device Trial